不同佐剂灭活非洲马瘟疫苗的安全性与效力研究
非洲马瘟病毒对马致死率约95%,现有减毒活疫苗存在安全问题。本研究在豚鼠和马中测试不同佐剂的灭活疫苗,发现加强免疫后部分佐剂可诱导高滴度中和抗体,但接种马并非全部能抵抗强毒攻击,且保护起效慢,不适合作为应急疫苗;灭活疫苗在病毒传播方面完全安全,DIVA原则可行。
要点
- 灭活非洲马瘟疫苗在病毒传播方面完全安全,但保护起效慢且需加强免疫,不适合应急使用。
- 不同佐剂影响中和抗体滴度,加强免疫后部分佐剂可诱导高滴度,但接种马并非全部存活强毒攻击。
- 多数存活马出现短暂临床症状和病毒血症,需更优佐剂以兼顾保护力与局部反应。
核心结论
- 当前原型灭活非洲马瘟疫苗完全安全但保护起效慢且需加强免疫,不适合作为应急疫苗。
研究设计与样本
- 在豚鼠和马中研究不同佐剂的灭活非洲马瘟疫苗,马中比较皮下与肌内接种途径。
主要发现
- 首次接种后中和抗体滴度普遍很低,加强免疫后部分佐剂可诱导高滴度中和抗体。
- 依据局部反应和中和抗体滴度选择接种马进行效力研究,但并非所有接种马存活强毒攻击。
- 多数存活马短暂出现临床症状和病毒血症。
- 灭活疫苗在病毒传播方面完全安全,基于NS3/NS3a血清学的DIVA原则可行。
关键数值与推荐
- 非洲马瘟在未免疫马中死亡率约95%。
- 非洲马瘟病毒有9个血清型,交叉中和抗体无或低。
临床怎么用
- 灭活非洲马瘟疫苗可用于避免病毒传播,但需加强免疫且保护起效慢,不适用于应急免疫。
- 需开发不引起局部反应且能增强保护应答的优良佐剂,以研制可负担且可接受的灭活疫苗。
局限性
- 接种马并非全部存活强毒攻击,多数存活马出现短暂临床症状和病毒血症。
- 当前原型灭活疫苗保护起效慢且需加强免疫,不适合应急使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
African horse sickness virus (AHSV) is a virus species in the genus Orbivirus of the family Reoviridae causing African Horse Sickness (AHS) in equids with a mortality of about 95% in naïve horses. AHS causes serious losses in developing countries where horses play a central role in draft power and transportation. There are nine AHSV serotypes inducing no or low cross-neutralizing antibodies. AHSV is spread by biting Culicoides midges. AHS is endemic in sub-Saharan Africa, and a serious threat outside Africa, since Culicoides species in moderate climate conditions are spreading the closely related bluetongue virus. AHS outbreaks will be devastating for the equestrian industry in developed countries. Live-attenuated vaccines (LAVs) are licensed, marketed and in use in Africa. Their application is controversial with regard to safety issues. LAVs are not allowed in AHS-free countries. We here studied inactivated AHSV with different adjuvants in guinea pigs and horses. Subcutaneous and intramuscular vaccination were studied in horses. Local reactions were observed after prime and boost vaccination. In general, neutralizing antibodies (nAbs) titres were very low after prime vaccination, whereas boost vaccination resulted in high nAb titres for some adjuvants. Vaccinated horses were selected based on local reactions and nAb titres to study efficacy. Unfortunately, not all vaccinated horses survived virulent AHSV infection. Further, most survivors temporarily developed clinical signs and viremia. Further, the current prototype inactivated AHS vaccine is not suitable as emergency vaccine, because onset of protection is slow and requires boost vaccinations. On the other hand, inactivated AHS vaccine is completely safe with respect to virus spread, and incorporation of the DIVA principle based on NS3/NS3a serology and exploring a vaccine production platform for other serotypes is feasible. A superior adjuvant increasing the protective response without causing local reactions will be required to develop payable and acceptable inactivated AHS vaccines.
引用
- van Rijn PA, Maris-Veldhuis MA, Grobler M, et al. Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants. Vaccine. 2020. PMID: 32921506. doi:10.1016/j.vaccine.2020.08.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。